Cargando…
Why not consider an endothelin receptor antagonist against SARS‐CoV‐2?
Autores principales: | Javor, S., Salsano, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194813/ https://www.ncbi.nlm.nih.gov/pubmed/32361169 http://dx.doi.org/10.1016/j.mehy.2020.109792 |
Ejemplares similares
-
Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015) -
Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023) -
The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis
por: Kowalczyk, Agata, et al.
Publicado: (2014) -
Synergistic and Antagonistic Drug Combinations against SARS-CoV-2
por: Bobrowski, Tesia, et al.
Publicado: (2021) -
Antidiuretic Effects of the Endothelin Receptor Antagonist Avosentan
por: Baltatu, Ovidiu Constantin, et al.
Publicado: (2012)